Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
HLXB Stock Forecast 2025-2026
$9.65
Current Price
$226.86M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to HLXB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
HLXB Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-8.4%
1 Year Change
-8.1%
Year-to-Date Change
-16.7%
From 52W High of $11.59
+13.5%
From 52W Low of $8.50
๐ TOP ANALYST CALLS
Did HLXB Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Helix Acquisition is one of their latest high-conviction picks.
Latest HLXB Stock Price Targets & Analyst Predictions
HLXB has shown a year-to-date change of -8.1% and a 1-year change of -8.4%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for HLXB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HLXB Analyst Ratings
0
Buy
0
Hold
0
Sell
HLXB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $9.65
Latest HLXB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HLXB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Helix Acquisition Corp II (HLXB) Competitors
The following stocks are similar to Helix Acquisition based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Helix Acquisition Corp II (HLXB) Financial Data
Helix Acquisition Corp II has a market capitalization of $226.86M with a P/E ratio of 47.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +4.0%.
Valuation Metrics
Market Cap
$226.86M
Enterprise Value
$232.07M
P/E Ratio
47.1x
PEG Ratio
-0.8x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
-58.5%
Financial Health
Cash/Price Ratio
+0.3%
Current Ratio
0.3x
Debt/Equity
0.0x
ROE
+4.0%
ROA
+3.9%
๐ก SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Helix Acquisition Corp II (HLXB) Business Model
About Helix Acquisition Corp II
What They Do
Facilitates mergers in healthcare and life sciences.
Business Model
The company operates as a special purpose acquisition company (SPAC) that raises capital through an initial public offering (IPO) to merge with or acquire businesses in the healthcare and life sciences sectors. It leverages its managerial expertise to identify companies with strong growth potential, particularly in biotechnology, pharmaceuticals, and medical technologies, allowing them to go public without the traditional IPO process.
Additional Information
Helix Acquisition Corp II offers a streamlined pathway for private companies to access public markets, which can lead to accelerated growth opportunities after merging. As part of the growing trend of SPACs, it serves as an alternative investment vehicle, connecting private enterprises with the resources they need to scale and enhance their market presence.
Helix Acquisition Corp II (HLXB) Latest News & Analysis
Latest News
Quick Summary
On August 11, 2025, Helix Acquisition Corp. II completed a business combination and closed a $261 million PIPE investment led by Cormorant Asset Management.
Why It Matters
The completion of the SPAC merger and substantial PIPE investment signals confidence in the company's future growth, potentially boosting stock value and attracting further investment interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Helix Acquisition Corp. II retains $120 million in its trust account, over 60% of cash, following redemptions by shareholders. The deadline for redemptions was July 31, 2025.
Why It Matters
Helix Acquisition Corp. II retains over $120 million in trust, indicating strong investor confidence and liquidity, which could drive future growth and stability for the merger with BridgeBio Oncology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics announced that their business combination registration has been declared effective by the SEC. An extraordinary general meeting is set for August 4, 2025.
Why It Matters
The SEC's approval of the business combination between Helix and BBOT signals progress in the SPAC's merger, potentially enhancing BBOT's market position and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BridgeBio Oncology Therapeutics and Helix Acquisition Corp. II have announced a definitive business combination, moving forward with their clinical-stage biopharmaceutical initiatives targeting RAS and PI3Kฮฑ malignancies.
Why It Matters
The merger between BridgeBio Oncology and Helix Acquisition Corp. signals potential growth in the biopharmaceutical sector, particularly in targeted cancer therapies, affecting investment strategies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Helix Acquisition Corp. II closed its IPO on February 13, 2024, raising $184 million by offering 18.4 million Class A shares at $10 each, including an over-allotment of 2.4 million shares.
Why It Matters
Helix Acquisition Corp. II raised $184 million in its IPO, indicating strong investor interest and potential for growth, which may influence stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About HLXB Stock
What is Helix Acquisition Corp II's (HLXB) stock forecast for 2026?
Analyst forecasts for Helix Acquisition Corp II (HLXB) are not currently available. The stock is trading at $9.65.
Is HLXB stock a good investment in 2026?
Analyst ratings for HLXB are not currently available. The stock is currently trading at $9.65. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HLXB stock?
Price predictions from Wall Street analysts for HLXB are not currently available. The stock is trading at $9.65.
What is Helix Acquisition Corp II's business model?
The company operates as a special purpose acquisition company (SPAC) that raises capital through an initial public offering (IPO) to merge with or acquire businesses in the healthcare and life sciences sectors. It leverages its managerial expertise to identify companies with strong growth potential, particularly in biotechnology, pharmaceuticals, and medical technologies, allowing them to go public without the traditional IPO process.
What is the highest forecasted price for HLXB Helix Acquisition Corp II?
Price targets from Wall Street analysts for HLXB are not currently available. The stock is trading at $9.65.
What is the lowest forecasted price for HLXB Helix Acquisition Corp II?
Price targets from Wall Street analysts for HLXB are not currently available. The stock is trading at $9.65.
What is the overall HLXB consensus from analysts for Helix Acquisition Corp II?
Analyst ratings for HLXB are not currently available. The stock is trading at $9.65.
How accurate are HLXB stock price projections?
Stock price projections, including those for Helix Acquisition Corp II, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 7, 2025 10:24 AM UTC